HIV-1 vaccine
First Phase I human clinical trial of a killed whole HIV 1 vaccine: demonstration of its safety and enhancement of anti HIV antibody responses
... for HIV-1 vaccine despite the ability of inactivated but intact whole-virus vaccines to generate a strong, predominantly antibody- mediated immune response in ...important HIV-1 viral ...
16
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
... GOVX-B11 vaccine expresses the native ADA (clade B) gp160 Env, a clade B CCR-5-tropic Env from a chronic infection ...RV144 HIV-1 vaccine phase 2b trial that demonstrated an estimated ...31.2% ...
18
Characterization of transgene expression in adenoviral vector based HIV 1 vaccine candidates
... based HIV-1 vaccine, transgene expression in non-per- missive cells in vitro can be reproducibly modulated by the presence of additional replication-incompetent aden- ...Table 1: Fold-increase ...
7
HIV 1 vaccine immunogen design strategies
... type 1 (HIV-1) vaccine is expected to have the greatest impact on HIV-1 spread and remains a global scientific ...candidate vaccine has significantly reduced ...
11
Route of Adenovirus-Based HIV-1 Vaccine Delivery Impacts the Phenotype and Trafficking of Vaccine-Elicited CD8+ T Lymphocytes
... Candidate HIV-1 vaccine regimens utilizing intramuscularly ...rAd vaccine routing might alter the quality and anatomic distribution of vaccine-elicited CD8 ⴙ T lymphocytes remains ...
11
FCGR2C polymorphisms associate with HIV 1 vaccine protection in RV144 trial
... Figure 1 and Sup- plemental Table 1; supplemental material available online with this article; ...125 HIV-1–infected subjects (51 vaccine and 74 placebo) and the 205 uninfected ...
13
Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial
... in vaccine recipients expressing ...of vaccine-in- duced antibodies to a subtype B peptide that encompasses site 169 and the A*02-KMQKEYALL epitope was significantly greater in A*02 ⫹ than in A*02 ⫺ ...
14
HIV 1 vaccine development : evaluating mechanisms of CD8+ T cell avidity
... infected or tumor cells to control infection or tumor growth ••• NKT cells • Produce immunoregulatory cytokines to help clear ~ bacterial/parasitic infections and tumors ••• • Lysis of t[r] ...
176
Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain.
... effective vaccine against human immunodeficiency virus type 1 (HIV-1) must overcome problems associated with extensive genetic ...reported vaccine-induced protec- tion of chimpanzees ...
5
Cellular Immune Responses in Asymptomatic Human Immunodeficiency Virus Type 1 (HIV-1) Infection and Effects of Vaccination with Recombinant Envelope Glycoprotein of HIV-1
... at 1 g/ml, baculovirus- expressed HIV-1 LAI rp24 Gag (rp24; Protein Sciences) at 1 g/ml, or a mouse monoclonal antibody to CD3 (Immunotech/Coulter ...either HIV-1 ...at ...
7
Multifunctional T-Cell Characteristics Induced by a Polyvalent DNA Prime/Protein Boost Human Immunodeficiency Virus Type 1 Vaccine Regimen Given to Healthy Adults Are Dependent on the Route and Dose of Administration
... clinical vaccine study of a human immunodeficiency virus type 1 (HIV-1) vaccine regimen comprising a DNA prime formulation (5-valent env and monovalent gag) followed by a 5-valent Env ...
12
Current progress in the development of a prophylactic vaccine for HIV-1
... with HIV-1 compared with 51 of 8197 par- ticipants who received the ...preventing HIV-1 infection was found to be statistically ...The vaccine strategy had no effect, however, on the ...
18
Enhancing T-Cell Responses to Vaccination of HIV-1 infected Subjects on Antiretroviral Therapy
... biomarkers, HIV-1 infected individuals continue to exhibit functional issues in their T-cell immune responses to recall antigens and ...with HIV-1 at risk from opportunistic infections and co- ...
178
Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
... glycoprotein HIV vaccine, we were unable to demonstrate such an effect in mucosal and serum ...IIIB HIV-1 vaccine, increases in serum antibody responses were detected following ...
7
Poly and autoreactivity of HIV 1 bNAbs: implications for vaccine design
... of HIV-1 vaccine research is to elicit rou- tinely broadly neutralizing antibodies (bNAbs), which target conserved, functionally important determinants on the HIV-1 envelope (Env) and ...
8
HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates
... an HIV-1 vaccine. Current HIV-1 envelope glycoprotein (Env) vaccine candidates elicit predominantly tier 1 and/or autologous tier 2 virus neutralizing antibody (NAb) ...
22
Use of a novel enhanced DNA vaccine vector for preclinical virus vaccine investigation
... effective HIV-1 vaccine would need to elicit include non- neutralizing antibody responses as well as broadly neutralizing antibody responses, together with polyfunctional cytotoxic T cell responses ...
11
TLR3 agonist and CD40 targeting vaccination induces immune responses and reduces HIV 1 reservoirs
... of HIV-1 reservoirs and induction of anti–HIV-1 T cells are critical to control HIV-1 rebound after combined antiretroviral therapy ...persistent HIV-1 infection ...
11
An HIV-1 Mini Vaccine Induced Long-lived Cellular and Humoral Immune Responses
... of HIV particle could be of use (7, ...from HIV-1 is a strategy that could enable a strong stimulation of humoral and cellular immune ...against HIV infection ...of HIV proteins has ...
9
A Human Immunodeficiency Virus Prime-Boost Immunization Regimen in Humans Induces Antibodies That Show Interclade Cross-Reactivity and Neutralize Several X4-, R5-, and Dualtropic Clade B and C Primary Isolates
... that vaccine-induced Abs are not strain or even clade B specific, but rather are broadly cross-clade ...of HIV-1 subtypes B, D, and ...gp120 HIV-1 vac- cines were able to bind to ...
9